Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

SunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus BCG in BCG-naive high-risk NMIBC (trial in progress).

e.g. ESMO 2023 2407TiP. No published utDNA results found.

Urine tumor DNA